None of the dogs enrolled in the study tested positive for heartworms.
See Study Design
374 client-owned dogs of various breeds ranging from 6 months to 15 years of age.
Dogs received ProHeart 6 (n=280) at 0.17 mg/kg on Month 0 and Month 6 or tablets of an approved heartworm preventative medication (n=94) every 30 days for 365 days.
Antigen and microfilaria testing was performed prior to enrollment and at Months 3, 6 and 12.
Six Months of Efficacy
A unique mode of action (MOA) delivers sustained concentrations, providing six months of efficacy:
Slow-dissolving microspheres contain moxidectin and prolong its effects.
Moxidectin redistributes from plasma to adipose tissue.
Adipose tissue acts as a reservoir, allowing six months’ protection against heartworm disease.
IMPORTANT SAFETY INFORMATION: PROHEART 6 should be used in healthy dogs. Do not administer to sick, debilitated, underweight dogs or dogs that have a history of weight loss. Prior to administration, PROHEART 6 certified veterinarians should continue to assess patient health through a medical history, physical examination and if deemed appropriate, diagnostic testing. Continue to use caution when administering PROHEART 6 concurrently with vaccinations. Adverse events, including anaphylaxis, have been reported following the concomitant use of PROHEART 6 and vaccines. In some cases, anaphylactic reactions have resulted in death. Use with caution in dogs with pre-existing or uncontrolled allergic disease (food allergy, atopy or flea allergy dermatitis). Dogs receiving PROHEART 6 should be tested for existing heartworms as per the product label. In people, avoid PROHEART 6 contact with eyes. If contact with the eyes occurs, rinse thoroughly with water for 15 minutes and seek medical attention immediately. PROHEART 6 is available only to veterinarians through a restricted distribution program. Only certified veterinarians and staff can administer it. To obtain additional information including a copy of the product labeling, click here or call 1-888-ZOETIS1 (963-8471).
Data on file. ProHeart 6 Freedom of Information Summary, NADA 141-189.
Lok JB, Knight DH, Wang GT, et al. Activity of an injectable, sustained-release formulation of moxidectin administered prophylactically to mixed-breed dogs to prevent infection with Dirofilaria immitis. Am J Vet Res. 2001;62(11):1721-1726.
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
For animals. For health. For you.
This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.
Print
United States 
